Drug Development

With strong data for volixibat, brelovitug, and LIVMARLI, Mirum (MIRM) de-risks its pipeline and sets the stage for growth. Here's the analysis.

A Canadian company's sublingual tablet could replace injections for popular peptides, just as the FDA considers expanding access for millions of users.

New preclinical data shows Sharp Therapeutics' oral drug candidate could reverse key pathologies of the fatal genetic disorder, offering hope beyond symptom management.

Celebrating two decades of innovation, RadioMedix unveils promising new alpha therapy data for pancreatic cancer at the SNMMI 2026 annual meeting.

A new service from Syncell offers researchers an unprecedented, unbiased view of proteins at the nanoscopic level, aiming to find drug targets hidden in plain sight.

With a new CMO who has a drug approval under his belt, ImmunoGenesis is poised to advance its novel therapy for hard-to-treat 'cold' tumors.

A novel oncolytic bacteria therapy gains key approvals in the US and China, showcasing a new global development model enabled by CDMO Porton Advanced.

A novel drug aims to starve deadly brain tumors by rewiring their metabolism. BPGbio's upcoming ASCO update could signal a major shift for glioblastoma.

BeOne Medicines' immunotherapy TEVIMBRA gains key reimbursement nods, paving the way for Canada's first funded option for a rare head and neck cancer.

A new clinical trial is testing a therapy that treats donor kidneys before transplant, aiming to prevent a common virus that complicates 30% of cases.

Uncommon Productions' 'Cracking the Code' earns top honors, celebrating the biotech revolution and the power of scientific ingenuity.

Therini Bio's novel drug THN391 enters trials, targeting inflammation in diabetic eye disease, while a next-gen combo therapy aims to redefine care.

Sensorium Therapeutics advances SNTX-2643, a novel anxiety drug, while adding a new CMO and an expert advisory board to guide its clinical journey.

EOM Pharmaceutical gets FDA clearance for a trial on EOM613, a potential first-in-class treatment for cancer cachexia, a severe wasting syndrome.

NEOK Bio begins Phase 1 trials for two bispecific ADCs, a next-gen therapy aiming to outsmart tumor resistance and offer new hope for solid tumor patients.

New preclinical data shows RTY-406 could be a first-in-class therapy for PSC, a progressive liver disease with no effective treatments.

Vanda Pharmaceuticals' rare disease drug gets a key designation in Japan, unlocking major incentives and promising a new treatment for a severe skin disease.

With CHF 105 million in new funding, NUCLIDIUM is advancing its novel copper-based radiotheranostics for metastatic prostate and breast cancer.

This year's Shaw Prize honors scientists who turned a deadly leukemia into a curable disease and unraveled the secrets of stellar explosions.

Positive Phase 3 data for oral drug filgotinib offers new hope for thousands of axial spondyloarthritis patients who fail to respond to current therapies.